Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.38 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ether SCHEMBL7531159 | 0.96 | ALDH1A1 (0.52) | ALDH1A1TSHRLMNAHSD17B10THRB | |
| Ether SCHEMBL1234081 | 0.96 | ALDH1A1 (0.52) | ALDH1A1TSHRLMNAHSD17B10THRB | |
| Ether SCHEMBL3336965 | 0.96 | ALDH1A1 (0.52) | ALDH1A1TSHRLMNAHSD17B10THRB | |
| Ether SCHEMBL9353265 | 0.96 | ALDH1A1 (0.52) | ALDH1A1TSHRLMNAHSD17B10THRB | |
| Ether SCHEMBL164114 | 0.96 | — | — | |
| Ether SCHEMBL8865297 | 0.93 | ALDH1A1 (0.50) | ALDH1A1TSHRLMNAHSD17B10THRB | |
| Ether SCHEMBL10836087 | 0.93 | ALDH1A1 (0.50) | ALDH1A1TSHRLMNAHSD17B10THRB | |
| Ether SCHEMBL11301526 | 0.93 | ALDH1A1 (0.50) | ALDH1A1TSHRLMNAHSD17B10THRB | |
| Ether SCHEMBL4686512 | 0.90 | ALDH1A1 (0.48) | ALDH1A1TSHRLMNAHSD17B10THRB | |
| Ether SCHEMBL6524630 | 0.90 | ALDH1A1 (0.48) | ALDH1A1TSHRLMNAHSD17B10THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160008322-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP (CA) | 2016-01-14 | — | — | US | disclosed |
| US-20140314685-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20130171077-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2013-07-04 | — | — | US | disclosed |
| US-8008342-B2 | Ion channel modulating compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2011-08-30 | — | — | US | disclosed |
| US-20110207730-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2011-08-25 | — | — | US | disclosed |
| US-7875611-B2 | (+)-trans-[2-(4-morpholinyl)-1-[2-(2-naphthoxy)ethoxy)]; (1R,2R)/(1S,2S)-2-[1,4-dioxa-7-azaspiro[4.4]non-7-yl]-1-(1-naphthenethoxy)cyclohexanecyclohexane; treatment of arrhythmia and the production of analgesia and local anesthesia | CARDIOME PHARMA CORP. (CA) | 2011-01-25 | — | — | US | disclosed |
| US-20100056603-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2010-03-04 | — | — | US | disclosed |
| US-20100029639-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2010-02-04 | — | — | US | disclosed |
| US-7534790-B2 | Ion channel modulating compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2009-05-19 | — | — | US | disclosed |
| US-7524879-B2 | Ion channel modulating compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2009-04-28 | — | — | US | disclosed |
| EP-0375351-B1 | Phosphonic acid substituted steroids as steroid 5alpha-reductase inhibitors | SMITHKLINE BEECHAM CORP (US) | 1994-08-31 | — | — | EP | disclosed |
| EP-0375349-B1 | Phosphinic acid substituted steroids as inhibitors of steroid 5alpha-reductase | SMITHKLINE BEECHAM CORP (US) | 1994-08-31 | — | — | EP | disclosed |
| WO-1993015080-A1 | AZABICYCLO COMPOUNDS AS CALCIUM CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-08-05 | — | — | WO | disclosed |
| WO-1993015073-A1 | AZABRICYCLIC COMPOUNDS AS CALCIUM CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-08-05 | — | — | WO | disclosed |
| US-5026882-A | Phosphinic acid substituted steroids as inhibitors of steroid 5α-reductase | SMITHKLINE BEECHAM CORPORATION (US) | 1991-06-25 | — | — | US | disclosed |
| US-4946834-A | ACRYLATE ANALOGUES OF STEROIDAL SYNTHETIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1990-08-07 | — | — | US | disclosed |
| EP-0375351-A1 | Phosphonic acid substituted steroids as steroid 5alpha-reductase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1990-06-27 | — | — | EP | disclosed |
| EP-0375349-A1 | Phosphinic acid substituted steroids as inhibitors of steroid 5alpha-reductase | SMITHKLINE BEECHAM CORPORATION (US) | 1990-06-27 | — | — | EP | disclosed |
| US-4338453-A | Aminoalkyl-1,2,4-triazoles | THE UPJOHN COMPANY (US) | 1982-07-06 | — | — | US | disclosed |
| US-3991207-A | TETRAHYDRONAPHTHYLAMINES AND L-3,4-DIHYDROXYPHENYL-ALANINE | PFIZER INC. (US) | 1976-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130171077-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | ALDH1A1 1319/4885TSHR 2898/4885LMNA 2669/4885 |
| US-20110207730-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | ALDH1A1 1319/4885TSHR 2898/4885LMNA 2669/4885 |
| US-20100056603-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | ALDH1A1 1319/4885TSHR 2898/4885LMNA 2669/4885 |
| US-20160008322-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | ALDH1A1 1319/4885TSHR 2898/4885LMNA 2669/4885 |
| US-20140314685-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | ALDH1A1 1319/4885TSHR 2898/4885LMNA 2669/4885 |
| US-20100029639-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | ALDH1A1 1319/4885TSHR 2898/4885LMNA 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.